Outcomes for patients receiving optimal exposure to imatinib are similar to other TKI
Sub-optimal responses and treatment failures with imatinib may be address4ed by exposure evaluation and dosing optimization.12,13
Help avoid sub-optimal therapeutic response
Help identify potential non-adherence to therapy
Help reduce toxicity in patients receiving too much drug, potentially improving the patient’s quality of life
Poster presented at Asco
Publications of Interest
The use of drug combinations has transformed met- astatic colorectal cancer treatment, with fluorouracil (FU) remaining the cornerstone of this treatment.1-6 Although initial intensification of FU, in combina- tion with other drugs, is the widely used approach from the inception, questions arise as to when these regimens should be introduced, whether initially or as soon as a tumor escape is suspected.
5-Fluorouracil (5-FU) has been a mainstay of colorectal cancer (CRC) chemotherapy for more than 50 years. There have been efforts to personalize CRC therapy by identifying genetic factors that determine response, toxicity, and resistance to 5-FU.
In the treatment of cancer patients with cytotoxic drugs, a prime consideration is improving the therapy outcome by in- creasing efficacy while maintaining an acceptable toxicity pro- file.
5-Fluorouracil (5-FU) has remained the backbone of colorectal cancer (CRC) therapy for more than 50 years [1–5]. Compared with bolus dosing, continuous intravenous infusion of 5-FU has allowed for higher tolerable doses to be administered to patients, thereby enhancing clinical effectiveness
Text For Button
Text For Button